flatbird therapeutics

What flatbird therapeutics does

Flatbird Therapeutics is a clinical-stage biopharmaceutical company developing topical botanical interventions for women's health, with a primary focus on HPV infection and HPV-related cervical disease prevention. The company's core technology combines modernized Traditional Chinese Medicine with small-molecule immunomodulatory approaches, centered on a proprietary multi-compound formulation (berberine, baicalin, matrine, ellagic acid, emodin) that targets multiple stages of the HPV lifecycle including viral integration, replication, and capsid assembly. Its flagship commercial product is Quannuo Ning® (权诺柠), a thermo-sensitive intravaginal gel registered in China as a non-drug OTC topical health product (消字号), supported by a 200-participant real-world clinical study reporting an 88% HPV viral clearance rate at 6 months (95% CI: 83–92%).

The company operates an integrated R&D-to-market model under a tri-city footprint: global headquarters in New York, an innovation/R&D center in Nanjing, and a commercialization hub in Suzhou, China. Go-to-market is direct-to-consumer via a full-spectrum domestic distribution and supply chain system in China, with no disclosed pricing or channel partner details. The product portfolio includes CERLIMA® (described as a globally innovative topical gel targeting HPV via immune modulation) and Quannuoning®/Quannuo Ning® (a broad-spectrum botanical antiviral formulation), with three additional pipelines under active development spanning HPV-related cancer prevention, female reproductive immunology, and mucosal microenvironment regulation. Revenue mechanics are not publicly disclosed; the company is privately held and backed by ATP Ventures as a portfolio partner company.

Name

flatbird therapeutics

Legal name

Flatbird Therapeutics

Website

https://flatbirdtx.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

Flatbird Therapeutics is a clinical-stage biopharmaceutical company developing proprietary botanical topical gels (CERLIMA®, Quannuoning®/Quannuo Ning®) targeting HPV infection and cervical disease in women, registered as an OTC topical health product in China.

Ownership category

akta.pro rank

Product category

Women's Health Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)

SIC

Medicinal Chemicals & Botanical Products (2833), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Hand Sanitizers & Antibacterial Personal Care (CRADANAI)

Keywords

• Women's health therapeutics
• HPV intervention
• Antiviral biopharmaceuticals
• Topical immunomodulatory gel
• Cervical cancer prevention

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Product Sales (CERLIMA and Quannuoning): Commercialization of proprietary topical gel products. CERLIMA is a globally innovative topical gel targeting HPV via immune modulation. Quannuoning is a broad-spectrum botanical antiviral formulation (Quannuo Ning). Revenue from direct consumer product sales in China market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Flatbird Therapeutics develops and commercializes biopharmaceutical topical products for women's health, centered on anti-HPV intervention. Its primary commercial product, Quannuo Ning® (权诺柠™) Feminine Defense Antibacterial Care Gel, is a thermo-sensitive intravaginal gel based on a modernized TCM botanical formulation registered as a non-drug OTC topical health product in China. Clinical-stage pipeline assets include CERLIMA® (globally innovative topical gel targeting HPV via immune modulation) and Quannuoning® (broad-spectrum botanical antiviral formulation).

Product overview

Flatbird Therapeutics operates a multi-product portfolio focused on women's health, anti-HPV research, and HPV-related cancer prevention. The flagship products include CERLIMA® (a globally innovative topical gel targeting HPV via immune modulation) and Quannuoning® (a broad-spectrum botanical antiviral formulation), both leveraging modernized Traditional Chinese Medicine combined with small-molecule immunomodulatory technologies. The commercialized consumer product, 权诺柠™ (Quannuo Ning®) Feminine Defense Antibacterial Care Gel, provides a locally applied intervention for HPV-infected women, delivering a clinically observed 88% viral clearance rate and filling the post-HPV vaccine gap for women without vaccination coverage or in watch-and-wait clinical stages.

Differentiator

Problem solved

Functional benefit

Brands

• CERLIMA®: A globally innovative topical gel targeting HPV via immune modulation.
• Quannuoning®
• Quannuo Ning® (权诺柠)

Products and services

• CERLIMA® A globally innovative topical gel targeting HPV via immune modulation, developed as part of Flatbird Therapeutics' flagship product portfolio for women's health.
• Quannuoning®
• 权诺柠™ (Quannuo Ning®) Feminine Defense Antibacterial Care Gel A thermo-sensitive intravaginal gel (3g/tube, 7 tubes/box) featuring a proprietary multi-targeted botanical formulation (berberine, baicalin, matrine, ellagic acid, emodin) that achieved an 88% high-risk HPV viral clearance rate after 6 months in a real-world clinical study of 200 HPV-positive women (95% CI: 83–92%). Hormone-free, antibiotic-free, pH-compatible with the vaginal environment; registered as a non-drug (OTC topical health product, 消字号) in China with completed GMP-level production validation.

Quantifiable outcome

• 88% HPV viral clearance rate after 6 months of use (95% CI: 83–92%)
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Procare Health: Procare Health markets Papilocare, a topical vaginal gel positioned for HPV-related cervical lesion management and cervical-vaginal care. It is the closest direct peer to Flatbird's Quannuo Ning: same product format (topical gel), same target condition (HPV/cervical health), and same self-pay/OTC commercialization model.
• Giuliani SpA: Giuliani's DeflaGyn is a vaginal gel indicated as a medical device for HPV-related cervical lesions, with multi-target mechanisms and clinical evidence in HPV clearance. Like Flatbird, it competes in the topical HPV-intervention niche with a non-systemic, locally-acting formulation.

Broad incumbents

• Bayer AG (Women's Health): Bayer operates a broad women's-health franchise spanning contraception, menopausal therapy, and gynecological health across both pharmaceutical and consumer health channels. Its scale, distribution, and existing OB/GYN relationships make it a benchmark for what scale-up of a women's-health specialty platform looks like, and a likely strategic acquirer of differentiated assets like Flatbird.
• Organon & Co: Organon is a women's-health focused specialty pharma (spun out from Merck) with a portfolio across contraception, fertility, and reproductive health. As a pure-play women's-health strategic, Organon represents the most logical acquirer profile for a clinical-stage HPV/reproductive immunology platform like Flatbird.
• Hologic Inc: Global leader in HPV diagnostics (Aptima, ThinPrep) and cervical-health screening, with growing adjacency to therapeutic and interventional products in cervical care. While diagnostic-led today, Hologic's OB/GYN channel and cervical-health brand provide a natural partner or acquirer profile for an interventional HPV platform.
• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates, with both chemical-drug and TCM/biological product lines and an extensive domestic distribution network. Comparable to Flatbird as a Chinese end-to-end pharma-commercialization platform with TCM capabilities, but at vastly greater scale.
• Merck & Co (HPV franchise): Merck owns the dominant HPV vaccine franchise (Gardasil) and is actively expanding into HPV-related therapeutics. While a vaccine-leader rather than topical-therapy peer, Merck defines the standard-of-care landscape that any non-vaccine HPV intervention must differentiate against.

Regional players

• China Traditional Chinese Medicine Holdings: Listed Chinese TCM platform with a focus on modernized traditional formulas and an extensive distribution and GMP-manufacturing footprint in China. Comparable to Flatbird in commercializing TCM-origin, regulatory-cleared health products for women's reproductive and immunological indications, though at much larger scale.
• Yunnan Baiyao Group: One of China's largest botanical pharmaceutical groups, with a portfolio spanning oral, topical, and consumer-health products derived from traditional herbal formulations. Comparable to Flatbird in the modernization of TCM actives for non-prescription health products, although Yunnan Baiyao operates at far greater scale and brand recognition.

Emerging players

• Cosette Pharmaceuticals: US-based specialty generics and women's-health pharmaceutical company that builds and acquires niche prescription OTC products targeting OB/GYNs and women's-health consumers. Comparable as a focused women's-health platform executing a roll-up of differentiated clinical/consumer products, of which Flatbird could plausibly be a target.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/flatbird-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about flatbird therapeutics